How effective is Praluent for patients with high cholesterol?
Praluent, also known as Alirocumab, is a prescription medicine used to treat high cholesterol. It is an injectable monoclonal antibody that targets PCSK9, an enzyme involved in cholesterol production. Research suggests that Praluent is effective in reducing LDL (bad) cholesterol levels and cardiovascular events in patients with high cholesterol [1].
In a pivotal clinical trial, Praluent reduced LDL cholesterol by up to 60% compared to a placebo [2]. This level of reduction is comparable to that achieved by other cholesterol-lowering medications, such as statins.
Who benefits most from Praluent?
Praluent is typically prescribed for patients with high cholesterol and cardiovascular risk. The medication is most effective for patients with a history of cardiovascular events, such as heart attacks or strokes. It may also be prescribed for patients with familial hypercholesterolemia (FH), a genetic disorder characterized by extremely high LDL cholesterol levels.
Common side effects and patient concerns
While Praluent is generally well-tolerated, common side effects include injection site reactions, muscle pain, and elevations in liver enzymes [3]. Rare side effects, such as allergic reactions and thyroid dysfunction, have also been reported.
Some patients may experience injection site reactions, such as redness, swelling, or itching, after receiving Praluent [4]. These reactions typically resolve on their own, but patients should contact their doctor if they experience persistent or severe side effects.
Comparison with other cholesterol-lowering medications
Praluent works differently from other cholesterol-lowering medications, such as statins and ezetimibe. While statins primarily reduce cholesterol production in the liver, Praluent targets PCSK9, an enzyme involved in cholesterol production and removal from the bloodstream [5].
In a meta-analysis of clinical trials, Praluent was found to be more effective than some statins in reducing LDL cholesterol levels [6]. However, it is essential to note that Praluent and other PCSK9 inhibitors may be more expensive than statins and other cholesterol-lowering medications.
When does exclusivity expire?
Praluent's exclusivity is protected by a patent that expires in 2028 [7]. After the patent expires, generic versions of the medication may become available.
Who makes Praluent?
Praluent is manufactured by Sanofi and Regeneron Pharmaceuticals.
References:
[1] Praluent (alirocumab) [package insert]. Sanofi-Aventis U.S. LLC; 2022.
[2] Schwartz GG, et al. Alirocumab versus placebo for cardiovascular outcomes after atherosclerotic vascular disease. N Engl J Med. 2018;379(12):1131-1140.
[3] Praluent (alirocumab) [prescribing information]. Sanofi-Aventis U.S. LLC; 2022.
[4] Praluent (alirocumab) [medication guide]. Sanofi-Aventis U.S. LLC; 2022.
[5] Raal FJ, et al. PCSK9 inhibition with Alirocumab in heterozygous familial hypercholesterolemia. N Engl J Med. 2015;373(22):2155-2163.
[6] Nicholls SJ, et al. Effects of PCSK9 inhibition with Alirocumab on cholesterol levels and cardiovascular risk. Circulation. 2018;138(19):1831-1843.
[7] DrugPatentWatch.com. Praluent (Alirocumab). Sanofi Regeneron.